Clinical Trials Logo

Calcific Uremic Arteriolopathy clinical trials

View clinical trials related to Calcific Uremic Arteriolopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04195906 Completed - Calciphylaxis Clinical Trials

Phase 3 Study of SNF472 for Calciphylaxis

Calciphyx
Start date: February 12, 2020
Phase: Phase 3
Study type: Interventional

The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).

NCT ID: NCT02790073 Completed - Calciphylaxis Clinical Trials

Phase 2 Study With SNF472 in Calciphylaxis Patients

Start date: May 2016
Phase: Phase 2
Study type: Interventional

To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).

NCT ID: NCT02278692 Completed - Calciphylaxis Clinical Trials

Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy

VitK-CUA
Start date: March 2015
Phase: N/A
Study type: Interventional

Calcific uremic arteriolopathy a.k.a. calciphylaxis is a vascular calcification disorder seen in dialysis patients. Calcific uremic arteriolopathy has 60-80% one-year mortality and significant morbidity associated with non-healing and extremely painful skin lesions. At present, there is no effective treatment for calcific uremic arteriolopathy. Vitamin K is an important vitamin for inhibiting vascular calcification. It is known to increase the circulating levels of carboxylated Matrix Gla Protein, a potent inhibitor of vascular calcification. However, the effects of vitamin K supplementation in patients with calcific uremic arteriolopathy are unknown. The purpose of this study is to conduct a pilot randomized controlled trial to examine the effects of oral vitamin K supplementation on circulating levels of anti-calcification factor (carboxylated Matrix Gla Protein) and clinical outcomes in patients with calcific uremic arteriolopathy.